News

Knocking out drug side effects with supercomputing

A Stanford team employs the world’s most powerful supercomputer in drug design efforts
Rachel Marisa Harken Tom Abate
By Rachel Marisa Harken and Tom Abate
Nov. 21, 2020

Psychedelic drugs could be effective in treating psychiatric disorders such as depression and post-traumatic stress disorder, but medical use of these drugs is limited by the hallucinations they cause.

"What if we could redesign drugs to keep their benefits while eliminating their unwanted side effects?" asked Ron Dror, an associate professor of computer science at Stanford University. Dror's lab is developing computer simulations using the world's most powerful and smartest supercomputer for open science, the IBM AC922 Summit supercomputer at the Oak Ridge Leadership Computing Facility (OLCF), to help researchers do just that.

In an article published in Science, Dror's team describes discoveries that could be used to minimize or eliminate side effects in a broad class of drugs that target G protein-coupled receptors, or GPCRs. GPCRs are proteins found in all human cells. Lysergic acid diethylamide (LSD) molecules and other psychedelics attach to GPCRs—but so do about a third of all prescription drugs, including medications for allergies, blood pressure, and pain. So important is this molecular mechanism that Stanford professor Brian Kobilka shared the 2012 Nobel Prize in Chemistry for his role in discovering how GPCRs work.

When a drug molecule attaches to a GPCR, it can cause multiple simultaneous changes in the cell. Some of these changes might contribute to a drug's beneficial effects, but others can lead to less-than-desirable or even dangerous effects.

Supercomputing-890x319.jpg
Carl-Mikael Suomivuori, Stanford University
A visualization of two differing protein arrangements (conformations) for the angiotensin II type 1 receptor. The orange arrangement only allows for arrestin protein coupling, but the blue arrangement allows for both arrestin and g protein coupling. Simulations of receptor conformations can help researchers understand why some drugs cause unwanted side effects.

Using the OLCF's Summit and a computing cluster at Stanford, the team compared computer simulations of a GPCR with different molecules attached. Dror's team was then able to pinpoint how a drug molecule can alter the way a GPCR's atoms are ordered. Changing the protein's atomic arrangement affects the protein shape and can allow a drug molecule to deliver beneficial effects without side effects—something that has remained mysterious until now. Based on these results, the researchers designed new molecules that were shown computationally to cause beneficial changes in cells without unwanted changes. Although these designed molecules are not yet suitable for use as drugs in humans, they represent a crucial first step toward developing side-effect-free drugs.

Today, researchers typically test millions of drug candidates—first in test tubes, then in animals, and finally in humans—hoping to find a "magic" molecule that is both effective and safe, meaning that any side effects are tolerable. This massive undertaking typically takes many years and costs billions of dollars, and the resulting drug often still has some frustrating side effects.

The discoveries by Dror's team promise to allow researchers to bypass much of that trial-and-error work so that they can bring promising drug candidates into animal and human trials faster and with a greater likelihood of success.

Stanford postdoctoral scholar Carl-Mikael Suomivuori and former graduate student Naomi Latorraca led an 11-member team that included Robert Lefkowitz of Duke University, with whom Kobilka shared the Nobel Prize, and Andrew Kruse of Harvard University, Kobilka's former student.

"In addition to revealing how a drug molecule could cause a GPCR to trigger only beneficial effects, we've used these findings to design molecules with desired physiological properties, which is something that many labs have been trying to do for a long time," Dror said. "Armed with our results, researchers can begin to imagine new and better ways to design drugs that retain their effectiveness while posing fewer dangers."

Dror hopes that such research will eventually eliminate the dangerous side effects of drugs used to treat a wide variety of diseases, including heart conditions, psychiatric disorders, and chronic pain.

The team's simulations were performed under a computing allocation in the Innovative and Novel Computational Impact on Theory and Experiment program at the OLCF, a US Department of Energy (DOE) Office of Science User Facility located at DOE's Oak Ridge National Laboratory.

This story was written by Tom Abate at Stanford University and adapted by Rachel Marisa Harken at Oak Ridge National Laboratory.

Rachel Marisa Harken
Rachel Marisa Harken

Rachel Marisa Harken produces feature articles about the scientific research performed on the high-performance computing resources at Oak Ridge National Laboratory. Her focus is on fields such as biology, chemistry, physics, materials, fusion, and data science.

Tom Abate
Tom Abate

Tom Abate is a U.S. Navy veteran and former business owner who now works for Stanford University, helping to make scientific discoveries understandable and relevant to policy makers and the public.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

From the journals: JLR
Journal News

From the journals: JLR

Aug. 3, 2021

A molecular mechanism of liver disease treatment. How tissues regulate octanoate. A perilipin’s role in cholesterol balance.

Meet Stephanie Moon
Observance

Meet Stephanie Moon

Aug. 2, 2021

She studies messenger RNA regulation at the University of Michigan in Ann Arbor.

Researchers find a cell surface decorated with sugar-coated RNAs
News

Researchers find a cell surface decorated with sugar-coated RNAs

Aug. 1, 2021

Finding not just glycoproteins and glycolipids but also glycoRNA means “now there are three hands, and we don’t know what that third hand is doing.”

Unraveling the mysterious mutations that make delta the most transmissible COVID virus yet
News

Unraveling the mysterious mutations that make delta the most transmissible COVID virus yet

July 31, 2021

As of this week, the delta variant had caused at least 92% of the new infections in the United States, according to a research firm in Switzerland.

Cats communicate with the help of bacteria living in their butts
News

Cats communicate with the help of bacteria living in their butts

July 31, 2021

KittyBiome researchers want to study the cat microbiome to improve health and understand scent-based communication.

From the journals: JLR
Journal News

From the journals: JLR

July 29, 2021

Reversing alcoholism’s effects on lipid droplets. How HDL cholesterol might reduce COVID-19 risk. Shining light on the cholesterol–GPCR relationship. Read about recent papers on these topics in the Journal of Lipid Research.